Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in Stock

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) General Counsel Andrew Fisher sold 80,000 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $11.53, for a total transaction of $922,400.00. Following the transaction, the general counsel now owns 359,999 shares in the company, valued at $4,150,788.47. The trade was a 18.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Andrew Fisher also recently made the following trade(s):

• On Tuesday, April 29th, Andrew Fisher sold 26,072 shares of Verona Pharma PLC American Depositary Share stock. The stock was sold at an average price of $8.98, for a total transaction of $234,126.56.

Verona Pharma PLC American Depositary Share Trading Up 3.7%

Shares of VRNA traded up $3.40 on Friday, hitting $94.32. 1,089,012 shares of the stock traded hands, compared to its average volume of 1,321,145. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $8.03 billion, a P/E ratio of -47.16 and a beta of 0.21. The stock's 50 day moving average is $74.68 and its two-hundred day moving average is $62.24. Verona Pharma PLC American Depositary Share has a 1 year low of $14.14 and a 1 year high of $94.45.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to analysts' expectations of $41.47 million. As a group, sell-side analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on VRNA. Roth Capital restated a "buy" rating and set a $116.00 target price (up from $92.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday. HC Wainwright increased their price target on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the company a "buy" rating in a research report on Monday, June 2nd. TD Cowen initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, April 28th. They issued a "buy" rating and a $100.00 price target on the stock. Wells Fargo & Company increased their price target on shares of Verona Pharma PLC American Depositary Share from $107.00 to $138.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Cowen initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, April 28th. They issued a "buy" rating on the stock. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $94.56.

Hedge Funds Weigh In On Verona Pharma PLC American Depositary Share

Several institutional investors and hedge funds have recently modified their holdings of the company. Frazier Life Sciences Management L.P. lifted its stake in shares of Verona Pharma PLC American Depositary Share by 2.2% during the first quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company's stock valued at $219,539,000 after buying an additional 73,900 shares during the period. Wellington Management Group LLP raised its stake in Verona Pharma PLC American Depositary Share by 61.0% during the fourth quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock worth $140,492,000 after purchasing an additional 1,146,609 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Verona Pharma PLC American Depositary Share by 1.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company's stock worth $118,491,000 after purchasing an additional 32,748 shares during the period. RTW Investments LP purchased a new position in Verona Pharma PLC American Depositary Share during the fourth quarter worth approximately $84,568,000. Finally, Janus Henderson Group PLC raised its stake in Verona Pharma PLC American Depositary Share by 59.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock worth $77,466,000 after purchasing an additional 624,370 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.